ME - 23andMe Holding Co.
NASDAQ
->
Healthcare
->
Diagnostics & Research
Sunnyvale,
United States
Type: Equity
ME price evolution
ME
| (in millions $) | 1 May 2025 | 31 Jan 2025 | 30 Oct 2024 | 30 Jul 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $24.83 | $27.77 | ||
| Inventory | $14.85 | $14.75 | ||
| Total current assets | $188.78 | $232.95 | ||
| Long term investments | ||||
| Property, plant & equipment | $69.92 | $73.64 | ||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $318.94 | $368.05 | ||
| Current liabilities | ||||
| Accounts payable | $6.49 | $11.19 | ||
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $152.83 | $152.86 | ||
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $217.01 | $224.54 | ||
| Shareholders' equity | ||||
| Retained earnings | -$2301.59 | -$2242.49 | ||
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2025 | 1 May 2024 | 1 May 2023 | 1 May 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $386.85 | $553.18 | ||
| Short term investments | ||||
| Net receivables | $1.9 | $3.38 | ||
| Inventory | $10.25 | $10.79 | ||
| Total current assets | $424.99 | $601.79 | ||
| Long term investments | ||||
| Property, plant & equipment | $94.69 | $105.43 | ||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $942.6 | $1152.07 | ||
| Current liabilities | ||||
| Accounts payable | $12.92 | $37.93 | ||
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $149.42 | $153.24 | ||
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $228.66 | $236.41 | ||
| Shareholders' equity | ||||
| Retained earnings | -$1506.38 | -$1194.73 | ||
| Other shareholder equity | -$0.62 | $0.18 | ||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $44.07 | $40.41 | $64.03 | $44.75 |
| Cost of revenue | ||||
| Gross Profit | $22.41 | $20.51 | $27.03 | $19.94 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $81.33 | $92.47 | $85.95 | $100.85 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.04 | $0.02 | $0.02 | |
| Interest expense | $2.01 | $2.57 | $3.04 | $3.23 |
| Net income | ||||
| Net income | -$59.1 | -$69.4 | -$208.83 | -$277.98 |
| Income (for common shares) | ||||
| (in millions $) | 1 May 2024 | 1 May 2023 | 1 May 2022 | 1 May 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $219.64 | $299.5 | $271.89 | $243.92 |
| Cost of revenue | ||||
| Gross Profit | $99.38 | $134.5 | $132.94 | $117.01 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $418.36 | $458.5 | $387.1 | $302.21 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.07 | -$2.8 | -$3.48 | |
| Interest expense | $14.33 | $9.7 | $0.28 | $1.58 |
| Net income | ||||
| Net income | -$666.7 | -$311.7 | -$217.49 | -$183.62 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$3.86 | -$1.16 | -$9.63 | -$7.48 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $0.27 | $0.01 | $3.58 | $1.58 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$87.79 | -$44.42 | -$170.36 | -$144.43 |
| (in millions $) | 1 May 2024 | 1 May 2023 | 1 May 2022 | 1 May 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$9.63 | -$11.31 | -$108.14 | -$6.54 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $3.58 | $9.78 | $546 | $155.34 |
| Effect of exchange rate | $0.39 | -$0.15 | ||
| Change in cash and equivalents | -$170.36 | -$166.53 | $270.88 | $74.55 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $193.26M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$615.31M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |